What the Data Shows About Bariatric Surgery Success Rates

Bariatric surgery achieves an average excess weight loss of 60–80% within the first two years, with around 50–60% maintained at five years and beyond. By the clinical benchmark of ≥50% excess weight loss, the procedure has a long-term success rate of approximately 68–74%, while studies show sustained benefits for up to 20 years after gastric bypass. Success extends beyond weight: type 2 diabetes goes into remission in 60–80% of patients, hypertension resolves in 60–70%, and sleep apnea improves or resolves in around 80% of cases. Outcomes vary by procedure, with duodenal switch and SADI-S producing the highest weight loss, while sleeve gastrectomy and gastric bypass remain the most performed worldwide.

The overall long-term success rate of bariatric surgery sits between 68% and 74%, with most patients maintaining 50–75% of their excess weight loss over the long term. Beneficial effects on weight have been documented for up to 20 years after gastric bypass surgery in long-term registries.

Initial weight loss is rapid and substantial. Patients lose 60–80% of their excess weight within the first 12–24 months, with maximum loss usually reached at the 18–24 month mark. After this point, the trajectory shifts toward maintenance, and some degree of regain becomes statistically common. Around 20–30% of patients experience clinically significant weight regain within the first two years of surgery, though most still maintain a major net loss compared with their pre-surgery baseline.

Long-term follow-up data from gastric bypass cohorts illustrates the maintenance pattern clearly. At 12 years post-surgery, 93% of patients maintained at least 10% weight loss from baseline, 70% maintained 20% loss, and 40% maintained at least 30% loss. These figures confirm that while weight regain affects a meaningful portion of patients, the majority retain a substantial fraction of their initial loss permanently.

Bariatric surgery fails to produce adequate weight loss in 15–35% of patients during the first two years, with failure defined as less than 50% excess weight loss. Long-term failure rates including significant weight regain can reach 30%, although figures vary by procedure and by how strictly failure is defined. Patients whose initial procedure fails often benefit from revision surgery to restore weight loss and comorbidity control.

• Non-adherence to Diet: Returning to high-calorie or high-frequency eating patterns is the leading behavioural cause of failure.
• Lack of Follow-up: Patients who skip scheduled post-op visits show consistently worse outcomes and higher revision rates.
• Anatomical Changes: Pouch dilation, stoma enlargement after bypass, or sleeve dilation can restore stomach capacity and undermine restriction.
• Inadequate Procedure Selection: Choosing a restrictive procedure for a super-obese patient (BMI ≥50) often produces insufficient weight loss, with this group benefiting more from hypoabsorptive options.
• Psychological Factors: Untreated binge eating disorder, emotional eating, or major depression strongly predicts weight regain.
• Insufficient Physical Activity: Patients who do not establish a regular exercise routine show greater regain and weaker metabolic improvement.
• Medication-Related Weight Gain: Certain medications including some antidepressants and corticosteroids can promote regain even when other behaviours are well controlled.

Revision rates broadly track with failure rates. Around 19% of sleeve gastrectomy patients require revisional surgery within 10 years, while gastric bypass shows revision rates closer to 5–10% over the same period.

Success rates vary significantly across procedures, with hypoabsorptive surgeries producing the greatest weight loss and endoscopic procedures producing the most modest. The table below summarises clinical outcomes for each major option.

Procedure	%EWL at 1 Year	%EWL at 5 Years	Weight Regain Rate	T2D Remission
Gastric Sleeve	60–70%	50–60%	25–35% at 10 years	45–65%
Gastric Bypass (RYGB)	70–80%	60–70%	20% at 10 years	60–75%
Mini Bypass (OAGB)	80–86% at 1 year	70–75%	<15%	70–80%
Transit Bipartition	70–80% at 1 year	Data emerging	Low	70–85%
SADI-S	70–87%	80–87%	Low	80–90%
Duodenal Switch	75–80%	80%	Lowest of all procedures	85–95%
Gastric Balloon	10–15% TWL at 6 months	Not applicable	Common after removal	20–30% improvement
Gastric Botox	5–15% body weight at 6 months	Not applicable	Common after 4–6 months	Modest

The figures above represent average outcomes from published clinical series. Individual results vary based on starting BMI, age, adherence, and comorbidity profile.

The duodenal switch produces the highest long-term weight loss of any bariatric procedure, with a multicenter study reporting 80.5% EWL at five years for traditional DS compared to lower figures for SADI-S in the same cohort. Bon Secours data shows SADI-S maintains 87% EWL at five years and 80% at ten years, placing it close to DS while carrying a lower complication risk. The trade-off is that hypoabsorptive procedures carry higher rates of nutritional deficiencies, with one long-term study reporting transient vitamin and micronutrient deficiencies in 44.8% of BPD/DS patients and 63.5% of SADI-S patients.

These weight loss figures partly reflect that duodenal switch and SADI-S are older, more established techniques with longer follow-up data available. Gastric bypass and transit bipartition deliver comparable outcomes when weight loss and surgical safety are evaluated together, which is why they remain the more commonly recommended options for most candidates.

Bariatric surgery resolves or substantially improves type 2 diabetes in 60–80% of patients, with similarly strong outcomes for hypertension, sleep apnea, and dyslipidemia. The STAMPEDE trial established the long-term superiority of metabolic surgery over medical therapy alone, and its findings remain the strongest evidence base for surgery as a treatment for diabetes surgery candidates.

• Type 2 Diabetes: Remission rates range from 45–65% at 10 years for sleeve gastrectomy and 60–75% for gastric bypass, with the STAMPEDE trial showing 29% of bypass patients and 23% of sleeve patients achieved HbA1c ≤6.0% at five years compared to just 5% on medication alone.
• Hypertension: Resolution occurs in 60–70% of patients post-surgery, with one University of Iowa figure citing 70–80% of patients on antihypertensive medication able to stop all medications within six months.
• Obstructive Sleep Apnea: Approximately 80% of patients experience resolution or significant improvement, with 16% of sleeve gastrectomy patients discontinuing CPAP use by 10 years.
• Dyslipidemia: Improvement or resolution occurs in around 70% of patients, with gastric bypass producing significantly higher resolution rates than sleeve gastrectomy in matched analyses.
• GERD: Gastric bypass resolves GERD in the majority of patients, while sleeve gastrectomy can trigger new-onset reflux in up to 42.9% of patients in long-term follow-up.
• Joint Pain and Mobility: Sustained improvements in joint function and mobility persist for most patients who maintain weight loss long-term.

The Oseberg trial confirmed that gastric bypass outperforms sleeve gastrectomy on diabetes remission at five years, while the STAMPEDE 5-year analysis showed that nearly 88% of gastric bypass and sleeve gastrectomy patients maintained healthy blood glucose levels without insulin.

A bariatric surgery is considered clinically successful when the patient loses at least 50% of excess weight and maintains that loss for five years or more. This benchmark, first defined by Halverson and Koehler, remains the most widely used standard in bariatric outcome research. To go deeper on the procedure itself, see our pillar on bariatric surgery.

Clinical success is measured through several quantifiable metrics, each capturing a different dimension of outcome.

• Percentage of Excess Weight Loss (%EWL): The proportion of weight above ideal body weight that the patient has lost; ≥50% is the standard success threshold.
• Percentage of Total Weight Loss (%TWL): The share of starting body weight lost overall; ≥20% TWL is increasingly used as a complementary success criterion.
• Comorbidity Resolution: Full or partial remission of obesity-linked conditions such as type 2 diabetes, hypertension, and sleep apnea.
• Weight Maintenance: Sustained loss measured at the five-year and ten-year marks, with regain below 25% of maximum loss considered acceptable.
• Quality of Life Improvement: Validated patient-reported outcome scores covering physical functioning, mobility, and psychological wellbeing.

A procedure that achieves rapid initial loss but fails to maintain that loss past two years is not classed as a success, which is why long-term follow-up data is the most meaningful measure.

Success depends on a combination of patient characteristics, procedure selection, and post-operative adherence, with no single factor predicting outcome on its own. Research consistently shows that the gap between top and bottom performers is driven more by behavioural and follow-up factors than by surgical technique.

• Starting BMI: Patients with lower initial BMI achieve a higher percentage of excess weight lost, while those with BMI ≥50 lose more total weight in absolute terms but a smaller proportion of excess weight.
• Age: Older patients consistently show worse weight loss outcomes; age is one of the most reliable predictors of failure in published cohorts.
• Type 2 Diabetes Status: Patients with pre-existing type 2 diabetes show less overall excess weight loss than non-diabetic patients undergoing the same procedure.
• Procedure Selection: Hypoabsorptive procedures produce greater weight loss than restrictive procedures, but at higher cost in nutritional risk and complication rate.
• Surgeon Volume and Experience: High-volume centres performing 200+ bariatric cases annually report 35–40% lower complication rates than low-volume centres.
• Follow-up Adherence: Regular attendance at scheduled follow-ups correlates strongly with better weight loss and lower revision rates.
• Diet and Exercise Compliance: Adherence to the post-op diet protocol and structured exercise programme is the single strongest behavioural predictor of long-term success.
• Psychological Profile: Patients with stronger self-efficacy and emotional adjustment show markedly higher success rates; one study found 46.5% of patients with the favourable personality profile achieved 90% EBL at 24 months versus less than 40% EBL for the contrasting group.

Most patients maintain 50–60% of their excess weight loss at five years and beyond, with documented benefit persisting for up to 20 years after gastric bypass. The weight loss curve follows a predictable pattern: rapid loss during months 0–12, plateau at 18–24 months, and a gradual partial regain in some patients beginning around year 5.

A 10-year follow-up study on sleeve gastrectomy found that mean percent weight loss persisted at 30.9% and mean %EWL at 52.5%, with significant weight regain occurring in only 10.4% of patients when defined as ≥25% of maximum weight lost. 

A 2023 systematic review of 1,020 sleeve patients reported weighted mean total weight loss of 24.4% at the 10-year mark. Importantly, weight regain does not necessarily compromise comorbidity remission; the same long-term sleeve cohort showed type 2 diabetes remission of 64.7% despite some patients experiencing regain.

For gastric bypass, long-term data is even stronger. Studies confirm 50–60% excess weight loss can be maintained 10–14 years after surgery, with sustained metabolic benefits even in patients who regain some weight. This durability makes gastric bypass a reference standard for long-term outcome comparisons.

Maximising success requires preparation before surgery and consistent adherence afterward, with the highest-performing patients treating the surgery as one stage in a long-term programme rather than a standalone event.

• Complete Thorough Pre-op Preparation: Follow the recommended pre-op diet, lose any required weight, and complete all medical workup; learn more about bariatric surgery pre surgery requirements.
• Choose the Right Procedure for Your Profile: Match procedure selection to your BMI, comorbidities, and lifestyle; super-obese patients benefit more from hypoabsorptive options than from restriction alone.
• Select a High-Volume Surgeon: Verify board certification, IFSO membership, and at least 200 annual cases at an accredited facility.
• Adhere to the Post-op Diet Protocol: Progress through the liquid, pureed, and solid phases on schedule and prioritise protein intake at every meal.
• Attend Every Scheduled Follow-up: Follow-up adherence is one of the strongest behavioural predictors of long-term weight maintenance.
• Take All Prescribed Supplements: Lifelong supplementation protects against the vitamin and micronutrient deficiencies that affect 44–63% of patients after hypoabsorptive procedures.
• Establish a Regular Exercise Routine: Combine resistance training with cardiovascular activity to preserve muscle mass and support metabolic health.
• Address Psychological Factors Proactively: Engage with counselling or support groups, especially if you have a history of disordered eating or depression.
• Quit Smoking Before Surgery: Stop smoking at least four to six weeks pre-op, as nicotine impairs healing and increases ulcer risk after bypass.

Bariatric surgery success rates in Turkey at accredited high-volume centres match international benchmarks, with complication and outcome figures broadly aligned with IFSO Global Registry data. The IFSO Global Registry 2023 collected data on almost 600,000 procedures from 35 countries, providing the most current international reference for comparison.

Metric	Turkey (Accredited Centres)	United States	United Kingdom
Average %EWL at 1 year (sleeve)	60–70%	60–70%	60–70%
Average %EWL at 1 year (bypass)	70–80%	70–80%	70–80%
Leak Rate (bypass)	0.4% (high-volume)	1–2%	1–2%
T2D Remission at 5 years	60–75% (bypass)	60–75% (bypass)	60–75% (bypass)
Annual Case Volume per Surgeon	High (200+ at accredited centres)	Variable	Variable

Outcomes at Turkish centres holding JCI accreditation and IFSO surgeon membership are statistically comparable to those at US and Western European centres. The differentiator is volume: surgeons at high-volume Turkish centres often perform over 200 procedures annually, which itself correlates with 35–40% lower complication rates.

Dr. Ceyhun Aydoğan brings 15 years of surgical experience to bariatric care, with outcomes that sit at the upper end of internationally reported benchmarks. His mortality rate stands at 0%, and his revision rate is 0.2%, meaning the likelihood of needing a second operation due to weight regain or insufficient weight loss is far below the 5–19% revision rates reported across published cohorts.

Several technical and clinical choices drive these numbers. In sleeve gastrectomy, Dr. Aydoğan reinforces the staple line with additional staple rows for greater structural integrity and reduced leak risk, and every procedure is followed by an intraoperative leak test before the patient leaves the operating room. Post-operative care is structured around close monitoring during the early recovery window, and each patient is paired with a dedicated dietitian whose follow-up protocol addresses the behavioural and nutritional factors that drive long-term success.

These outcomes reflect the standard expected of high-volume centres performing weight loss surgery in Turkey, where surgeon experience and structured aftercare are the variables that separate consistent long-term results from inconsistent ones.